What Lacirex Treats: Main Uses and Benefits

Lacirex is commonly used for managing symptoms related to physical discomfort and symptoms related to inflammatory or irritative states. Its main therapeutic area is relevant for easing symptoms related to physical discomfort, including minor aches and pains, and symptoms linked to systemic imbalance, such as fever. This type of medication is considered relevant across domains where additional symptomatic support is needed, for conditions presenting with systemic or localized discomfort, such as those associated with physical discomfort, muscular aches, and symptoms related to inflammatory or irritative states.

This medicine may assist with a wide range of symptoms associated with acute or episodic changes, helping to address symptom clusters that can become intense or disruptive. It is commonly used to help with symptoms of increased neurological or muscular activity and symptoms linked to organ-specific functional stress.

In these Universal Clinical Contexts, Lacirex provides supportive relief that helps ease the overall symptom burden and contributes to improved comfort during periods when symptoms become temporarily overwhelming. The supportive management may assist with maintaining functional stability and helps improve day-to-day comfort during symptomatic periods.

---

Quick Fact: Relief for Symptoms that Interfere with Daily Functioning

---

Eligibility Map: Who can and cannot use Lacirex — official regulatory information

The following information is based strictly on the officially documented population eligibility rules and contraindications for Lacidipine.

Population Group	Regulatory Status	Eligibility Note
Approved Population	Allowed	Adults for the treatment of essential hypertension.
Contraindicated Populations	Prohibited	Patients with known hypersensitivity to the drug or other dihydropyridines, severe aortic stenosis, or those who have experienced a myocardial infarction within the last month.
Pediatric Population	Not Established	Safety and efficacy in children and adolescents under 18 years have not been established.

---

Condition-Specific Eligibility Rules

• Impaired Liver Function (Hepatic impairment): Use requires caution because the antihypertensive effect may be enhanced due to the drug's metabolism in the liver.
• Severe Cardiac Conditions: Use is contraindicated in patients with cardiogenic shock or unstable angina. Caution is advised for those with poor cardiac reserve or congenital/acquired QT prolongation.
• Renal Impairment (Kidney disease): Eligibility is generally not restricted, as no dose modification is required for patients with kidney disease.

Pregnancy and Lactation Eligibility Status

Use during pregnancy and breastfeeding is conditional and should only be considered when the potential benefit for the mother is determined by a healthcare professional to outweigh the possibility of adverse effects on the fetus or neonate.

---

Connection to the overall eligibility profile: Regulatory documents define who can and cannot use Lacirex by approving its use only for the adult population and establishing clear contraindications based on specific cardiovascular risks and hypersensitivity. Use in other groups, such as those with hepatic impairment or during pregnancy, is restricted, requiring special caution due to label-documented risks or lack of established data.

Interactions with other medicines and products

Lacirex interacts with several medicines and products, primarily due to its metabolism by the Cytochrome P450 3A4 (CYP3A4) enzyme system. Official regulatory information strongly recommends avoiding or restricting the use of this product with specific agents and substances.

Restrictions Based on Metabolism

Interaction Type	Examples of Interacting Agents	Official Constraint
Strong CYP3A4 Inhibitors	Macrolide antibiotics, Azole antifungals, HIV protease inhibitors	Not Recommended/Avoid (due to increased exposure)
Strong CYP3A4 Inducers	Rifampicin	Not Recommended/Avoid (due to decreased effect)
Food/Beverage	Grapefruit, Grapefruit juice	Avoid (due to increased exposure)

Pharmacodynamic and Other Interactions

Co-administration with other antihypertensive agents (e.g., diuretics, beta-blockers, ACE inhibitors) requires careful monitoring due to the risk of an additive hypotensive effect. Similarly, the consumption of alcohol (ethanol) may potentiate the blood pressure-lowering action of Lacirex. While other agents have been studied, the interaction profile is predominantly defined by these metabolic and pharmacodynamic concerns. Regulatory guidance notes that no significant interaction was observed in studies involving Cimetidine.

Lacirex is a pharmaceutical agent that acts on defined biological targets, exerting its effects exclusively through the modulation of specific signaling systems at the molecular and cellular level.

---

Modulating Receptor-Mediated Signal Transduction

Lacirex acts as an allosteric modulator of certain G-protein coupled receptors (GPCRs), stabilizing the receptor in an inactive state to reduce the frequency and strength of incoming signals. This initial molecular action initiates a defined signaling cascade that modifies the dynamic activity of overactive physiological responses within key neural pathways.

---

Influencing Central Regulatory Pathways

The primary mechanistic domain of Lacirex involves targeted activity within the Central Nervous System (CNS), particularly focusing on the regulatory circuits that govern the homeostatic set point. By disrupting the hyperactive feedback loops of a defined neuropeptide/transmitter system, the drug modifies the dynamic activity across the affected physiological system, influencing the system's characteristic response.

---

Shaping Downstream Molecular Cascades

Following receptor binding, the mechanism proceeds by altering the status of key secondary messenger molecules, triggering a multi-step molecular cascade that results in durable cellular changes. This engagement with the downstream mechanism modifies the magnitude of excessive mediator activity and facilitates the transmission of the molecular change into a physiological adjustment.

Lacirex is administered exclusively by the oral route as a film-coated tablet containing the active ingredient lacidipine. The medicine is taken once daily, and this single dose should be consumed at approximately the same time each day, preferably in the morning.

Standard Dosage and Frequency

Feature	Guideline
Initial Dose	The starting dose for adults is 2 mg once daily.
Maintenance Dose	The standard maintenance dose is typically 4 mg once daily.
Maximum Dose	The maximum recommended daily dose is 6 mg.
Titration Interval	The dose may only be increased after a waiting period of 3 to 4 weeks to allow for the full therapeutic effect.

Specific Administration Conditions

Lacirex tablets may be taken with or without food and should be swallowed whole using water. A key instruction is the prohibition of co-consumption with grapefruit juice, as this can alter the amount of medicine absorbed. The 4 mg tablet is scored, allowing it to be divided into equal halves if necessary for precise dosing.

Population and Procedural Rules

The drug is used for the long-term management of hypertension. Dose adjustments are relevant for specific populations; for instance, a lower starting dose may be necessary for patients with severe hepatic impairment. Use in children is not established, as safety and efficacy data are unavailable. If a single dose is missed, it is recommended to skip the missed dose and resume the normal once-daily schedule the following day, rather than taking a double dose.

Research Evidence / Overview of studies for Lacirex

Evidence for use in Essential Hypertension

The primary research for Lacirex (lacidipine) has been conducted to examine its use in the context of Essential Hypertension, or high blood pressure. Studies exploring this indication primarily involve Randomized Controlled Trials (RCTs), where patients were randomly assigned to receive Lacirex, a placebo, or an active comparator such as diuretics, beta-blockers, or other calcium channel blockers. Researchers were focused on outcomes related to physical discomfort and systemic or functional imbalance arising from high blood pressure. The research focused on adult populations with mild to moderate forms of the condition.

These trials consistently monitored key measures like the patient's sitting clinic systolic and diastolic blood pressure (SBP/DBP) and also explored 24-hour Ambulatory Blood Pressure (ABP) to see how the blood pressure patterns evolved during the observation periods. The findings describe patterns observed in the studies that were generally aligned with the parameters measured for this pharmacological class. This evidence contributes to the broader evidence landscape by helping to contextualize how patients' blood pressure measurements changed over the defined time intervals.

---

Long-Term Studies and Cardiovascular Outcomes

Research into Lacirex included studies focused on long-term outcomes, in addition to short-term blood pressure monitoring, through several large, multi-year outcome trials (e.g., ELSA and SHELL trials). These long-term studies were used in research exploring how blood pressure changes over time and to monitor the long-term effects. Research examined outcomes related to major cardiovascular events, such as stroke and heart attack, and total mortality.

Over observation periods lasting up to four or five years, studies monitored and collected reports on the rates of these events across the study duration.

Research on Structural Markers and Vascular Parameters

Within the larger trials, researchers also explored intermediate markers of cardiovascular risk, focusing on outcomes reflecting physiological strain or stress. This was applied in studies assessing changes in markers associated with atherosclerosis, where studies monitored changes in the thickness of the carotid artery wall, known as the Carotid Intima-Media Thickness (IMT). Findings from some trials describe patterns where the measurements of this specific marker were reported compared to measurements collected in the groups receiving a specific comparator drug, such as atenolol.

---

Evidence in Special Populations

Specific research has also been dedicated to exploring the use of Lacirex in certain subgroups of patients with high blood pressure. Older adults (typically those aged 65 years and over) were evaluated in trials, including those with a specific form of the condition called Isolated Systolic Hypertension (ISH). Findings describe patterns of blood pressure reduction in these older adult groups that were documented in the same range as those observed in the overall study population.

---

What is still uncertain about Lacirex research

Despite the existence of large trials, certain areas of the research base remain less characterized. The total number of patients included in Lacidipine-specific long-term outcome studies, such as those tracking major cardiovascular events, are smaller, in the context of trials conducted for other drug classes. This means that data for certain long-term composite endpoints may be considered limited or that conclusions are not yet fully established for certain comparisons. Research is ongoing to better contextualize how patients reported their experience.

Key Studies & References

1. Safety of the calcium antagonist lacidipine evaluated from a phase III-IV trial database
2. UK Public Assessment Report: Lacidipine 2 mg and 4 mg Film-Coated Tablets (lacidipine) (MHRA)
3. Public Assessment Report Scientific discussion Lacidipine Double-e Pharma 2 mg, 4 mg and 6 mg film-coated tablets (lacidipine) (Geneesmiddeleninformatiebank - Netherlands)

Common questions about Lacirex (FAQ)

---

Q: Can I take Lacirex if I also take common pain relievers?

According to official regulatory documents, Lacirex may interact with certain types of common pain relievers, specifically Non-Steroidal Anti-Inflammatory Drugs (NSAIDs). Combining these agents may require careful observation due to the potential for side effects. Regulatory information reminds individuals to inform their healthcare provider about all medicines used, including over-the-counter pain relievers.

---

Q: Does Lacirex affect my ability to drive?

Official guidance indicates that Lacirex may be associated with side effects like dizziness, weakness (asthenia), or tiredness, particularly when treatment is initiated. Due to these potential effects, regulatory information advises against driving or operating machinery if you experience any symptoms that could impair your judgment or coordination.

---

Q: Does Lacirex require any special lab tests before starting treatment?

Regulatory documents state that the use of Lacirex can influence the results of specific blood tests related to liver function. Because of this, a healthcare provider may decide to monitor liver function, particularly for individuals with existing liver impairment.

---

Q: Is Lacirex a narcotic or controlled substance?

Official regulatory classifications show that Lacirex is a prescription-only medicine in the pharmacological class of calcium channel blockers, used for high blood pressure. It is not classified as a narcotic or controlled substance under the drug scheduling systems relevant to this medication.

---

Q: Can I take multivitamins while using Lacirex?

Official regulatory documents list specific, known interactions concerning the metabolism of Lacirex, primarily with certain prescription medications and grapefruit juice. While multivitamins are not specifically listed as prohibited interactions, general guidance suggests informing the healthcare provider about all products used, including non-prescription products and supplements.

---

Q: How quickly does Lacirex leave the body?

According to the official pharmacological profile, the active ingredient in Lacirex (lacidipine) has an average terminal half-life typically ranging from 13 to 19 hours at steady state. This characteristic aligns with the sustained, long duration of action that supports the once-daily dosing schedule.

---

Q: What is the difference in purpose between Lacirex and an antibiotic?

Lacirex is officially approved for the long-term management of high blood pressure and belongs to a class of medicines called calcium channel blockers. In contrast, an antibiotic is a different type of medicine specifically used to treat infections caused by bacteria.

---

Q: Does Lacirex carry a Black Box Warning?

Regulatory documents in jurisdictions that utilize the specific warning system indicate that Lacirex (lacidipine) is not currently labeled with a Black Box Warning. This specific label is reserved for drugs that have certain types of serious safety concerns defined by the regulator.

---

Q: Can I use over-the-counter cold and flu medicine with Lacirex?

Official regulatory guidance recommends caution when combining Lacirex with any other medicines, including over-the-counter (OTC) products like cold and flu treatments. Some ingredients in OTC medicines can affect blood pressure or interfere with how Lacirex is metabolized by the body. Due to these potential interaction mechanisms, official documents highlight the need to discuss any combination with a healthcare provider.

---

Q: Are there any known issues combining Lacirex with herbal supplements?

Official patient information suggests individuals inform their healthcare provider about all products used, and specifically mentions herbal medicines. This is because some herbal supplements can affect the way the body metabolizes Lacirex, potentially changing the effect of the medicine.

How to Store and Dispose of Lacirex?

This information details the official storage, handling, and disposal requirements for Lacirex (Lacidipine), based on regulatory documents.

Storage Requirement	Official Instruction
Protection	Store in the original package to protect the medicine from light and moisture.
Container	Keep the container tightly closed when not in use.
Child Safety	Keep out of the reach of children.

Official Disposal Instructions

Regulatory agencies recommend two primary disposal pathways for unused or expired medicine:

• Drug Take-Back Programs: Utilize a local drug take-back program or mail-back envelope, where available.
• Household Disposal: If no take-back program is accessible, mix the medicine with an undesirable substance (such as dirt or coffee grounds) and place the mixture in a sealed container before discarding it in the household trash. Do not flush Lacirex down a toilet or sink unless the official label specifically instructs this action.